https://www.pharmaradar360.com/article/maharashtra-fda-suspends-licences-of-these-5-clubs-in-mumbai-over-food-safety-vi-a7dbc221eeb8d8f9Pharma Surgeen2026-07-28T16:08:24.000ZMaharashtra FDA Suspends Licences of These 5 Clubs in Mumbai Over Food Safety Violations; Check Names Herehttps://www.pharmaradar360.com/article/fda-panel-to-consider-previously-spurned-drugs-44b94a38143acbaaPharma Surgeen2026-07-28T16:00:00.000ZFDA panel to consider previously spurned drugshttps://www.pharmaradar360.com/article/ono-pharmaceutical-partners-with-phylo-to-embed-agentic-ai-with-every-discovery-d1badd7aeb3202abPharma Surgeen2026-07-28T16:00:00.000ZOno Pharmaceutical partners with Phylo to embed agentic AI with every discovery scientisthttps://www.pharmaradar360.com/article/recordati-solid-momentum-of-the-group-continues-first-half-2026-net-revenue-6-6-ceed42b29aa53f86Pharma Surgeen2026-07-28T15:55:53.000ZRECORDATI: SOLID MOMENTUM OF THE GROUP CONTINUES FIRST HALF 2026. NET REVENUE +6.6%, EBITDA +8.8%, ADJUSTED NET INCOME +6.7%https://www.pharmaradar360.com/article/piper-sandler-raises-teva-pharmaceutical-industries-nyse-teva-price-target-to-44-59f350b2778ee99fPharma Surgeen2026-07-28T15:37:35.000ZPiper Sandler Raises Teva Pharmaceutical Industries (NYSE:TEVA) Price Target to $44.00https://www.pharmaradar360.com/article/kalshi-and-polymarket-now-let-you-bet-on-drug-approvals-and-not-everyone-is-thri-02ceded2bd1c461cPharma Surgeen2026-07-28T15:09:53.000ZKalshi and Polymarket now let you bet on drug approvals, and not everyone is thrilled about ithttps://www.pharmaradar360.com/article/fedrigoni-addresses-evolving-pharmaceutical-label-industry-9922c9577815c224Pharma Surgeen2026-07-28T15:03:59.000ZFedrigoni addresses evolving pharmaceutical label industryhttps://www.pharmaradar360.com/article/biotech-division-of-greenland-mines-announces-issuance-of-patent-in-canada-for-t-0bc0eb26588295abPharma Surgeen2026-07-28T15:01:11.000ZBiotech Division of Greenland Mines Announces Issuance of Patent in Canada for the Klotho Gene Therapy Platform Technology for Alzheimer’s and Aginghttps://www.pharmaradar360.com/article/fortress-biotech-and-subsidiary-urica-therapeutics-announce-crystalys-therapeuti-8f1463a6da0cd701Pharma Surgeen2026-07-28T15:00:17.000ZFortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics $130 Million Series B Financinghttps://www.pharmaradar360.com/article/record-chinese-biotech-out-licensing-meets-rising-us-scrutiny-b825d005ceb57a9aPharma Surgeen2026-07-28T15:00:09.000ZRecord Chinese biotech out-licensing meets rising US scrutinyhttps://www.pharmaradar360.com/article/gsk-cambridge-move-signals-shift-in-drug-scale-up-strategy-4a203e9a89242993Pharma Surgeen2026-07-28T14:50:08.000ZGSK Cambridge Move Signals Shift in Drug Scale-Up Strategyhttps://www.pharmaradar360.com/article/maplight-s-schizophrenia-candidate-clears-one-bar-but-misses-another-34d3c1d8817649cfPharma Surgeen2026-07-28T14:47:35.000ZMapLight's schizophrenia candidate clears one bar but misses anotherhttps://www.pharmaradar360.com/article/analysts-offer-insights-on-healthcare-companies-ultragenyx-pharmaceutical-rare-a-cebb543d446e1709Pharma Surgeen2026-07-28T14:42:37.000ZAnalysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and Danaher (DHR)https://www.pharmaradar360.com/article/leadership-changes-afoot-at-two-cgt-biotechs-eeb7c78b0f20f9a3Pharma Surgeen2026-07-28T14:37:26.000ZLeadership changes afoot at two CGT biotechshttps://www.pharmaradar360.com/article/takeda-pharmaceutical-company-limited-stock-12-month-price-target-raised-to-19-2-36ddddc12343fab6Pharma Surgeen2026-07-28T14:20:12.000ZTakeda Pharmaceutical Company Limited Stock 12‑Month Price Target Raised to $19.2, Implies 10% Upsidehttps://www.pharmaradar360.com/article/can-these-5-biotech-stocks-beat-wall-street-s-q2-estimates-92e305441879facePharma Surgeen2026-07-28T14:07:00.000ZCan These 5 Biotech Stocks Beat Wall Street's Q2 Estimates?https://www.pharmaradar360.com/article/questex-s-fierce-pharma-unveils-fierce-pharma-week-s-2026-conference-program-exp-4df986349607d825Pharma Surgeen2026-07-28T14:05:17.000ZQuestex’s Fierce Pharma Unveils Fierce Pharma Week’s 2026 Conference Program, Explores What’s Next in the Pharmaceutical Industryhttps://www.pharmaradar360.com/article/alnylam-s-stock-is-down-30-despite-a-booming-biotech-market-here-s-why-2be5df40cf7336b6Pharma Surgeen2026-07-28T14:00:00.000ZAlnylam’s stock is down 30% despite a booming biotech market. Here’s why.https://www.pharmaradar360.com/article/chmp-backs-roche-s-susvimo-as-first-continuous-namd-therapy-57161bf215b1c98ePharma Surgeen2026-07-28T13:55:08.000ZCHMP backs Roche’s Susvimo as first continuous nAMD therapyhttps://www.pharmaradar360.com/article/peli-biothermal-partners-with-paxafe-to-redefine-pharmaceutical-cold-chain-intel-b5b83d7ff56d5d9aPharma Surgeen2026-07-28T13:53:00.000ZPeli BioThermal Partners with PAXAFE to Redefine Pharmaceutical Cold Chain Intelligencehttps://www.pharmaradar360.com/article/china-s-biotech-rise-to-face-challenges-from-us-policy-responses-e5a9fe1e64dee365Pharma Surgeen2026-07-28T13:47:43.000ZChina’s biotech rise to face challenges from US policy responseshttps://www.pharmaradar360.com/article/nafdac-continued-enforcement-of-the-ban-on-sub-200ml-sachet-pet-bottle-alcoholic-7ae4497573e269b8Pharma Surgeen2026-07-28T13:46:24.000ZNAFDAC Continued Enforcement of the Ban on Sub-200ml Sachet & PET Bottle Alcoholic Products: Update on Nationwide Mop-Up Operation.https://www.pharmaradar360.com/article/brewing-up-biotech-tea-catechins-and-their-anti-aging-impact-0a4c84a4e0a6661fPharma Surgeen2026-07-28T13:44:15.000ZBrewing Up Biotech: Tea Catechins and Their Anti-Aging Impacthttps://www.pharmaradar360.com/article/brainstorm-appoints-former-fda-official-peter-pitts-executive-chairman-to-lead-p-356aea84f7ff6725Pharma Surgeen2026-07-28T13:42:51.000ZBrainStorm Appoints Former FDA Official Peter Pitts Executive Chairman to Lead Phase 3 ALS Strategyhttps://www.pharmaradar360.com/article/navigating-technology-transfer-in-pharma-and-biotech-4bb68da6177dd33fPharma Surgeen2026-07-28T13:32:41.000ZNavigating Technology Transfer in Pharma and Biotechhttps://www.pharmaradar360.com/article/sartorius-stedim-biotech-buy-rating-from-bernstein-68babfe212822d92Pharma Surgeen2026-07-28T13:25:40.000ZSARTORIUS STEDIM BIOTECH : Buy rating from Bernsteinhttps://www.pharmaradar360.com/article/edison-issues-report-on-bb-biotech-bion-2faa051cc07bfa27Pharma Surgeen2026-07-28T13:20:54.000ZEdison issues report on BB Biotech (BION)https://www.pharmaradar360.com/article/stay-ahead-of-the-game-with-teva-pharmaceutical-industries-teva-q2-earnings-wall-ac50ff948e147659Pharma Surgeen2026-07-28T13:15:04.000ZStay Ahead of the Game With Teva Pharmaceutical Industries (TEVA) Q2 Earnings: Wall Street's Insights on Key Metricshttps://www.pharmaradar360.com/article/amgen-makes-case-to-continue-selling-drug-that-fda-claims-can-be-deadly-29be1c75a6b766daPharma Surgeen2026-07-28T13:15:00.000ZAmgen makes case to continue selling drug that FDA claims can be deadlyhttps://www.pharmaradar360.com/article/recce-pharmaceuticals-asx-rce-advances-phase-3-trials-and-mena-licensing-strateg-aa9ab7489126863fPharma Surgeen2026-07-28T13:10:00.000ZRecce Pharmaceuticals (ASX:RCE) Advances Phase 3 Trials and MENA Licensing Strategy as Commercial Pathway Developshttps://www.pharmaradar360.com/article/an-eye-drug-biotech-banks-118m-and-stocks-its-executive-suite-d2ace487152d6c9ePharma Surgeen2026-07-28T13:07:30.000ZAn eye drug biotech banks $118M and stocks its executive suitehttps://www.pharmaradar360.com/article/legend-biotech-names-interim-ceo-after-ying-huang-steps-down-0a20a47794754831Pharma Surgeen2026-07-28T13:01:34.000ZLegend Biotech names interim CEO after Ying Huang steps downhttps://www.pharmaradar360.com/article/pharmaceutical-ad-urges-viewers-to-fight-doctors-who-say-drug-not-right-for-them-1f0a06e0564589b2Pharma Surgeen2026-07-28T13:00:00.000ZPharmaceutical Ad Urges Viewers To Fight Doctors Who Say Drug Not Right For Themhttps://www.pharmaradar360.com/article/ai-in-pharmaceutical-manufacturing-executive-handbook-on-ai-readiness-digital-ma-6083d2578091c4e1Pharma Surgeen2026-07-28T13:00:00.000ZAI in Pharmaceutical Manufacturing: Executive Handbook on AI Readiness, Digital Maturity and Factory Transformationhttps://www.pharmaradar360.com/article/codexis-to-report-second-quarter-2026-financial-results-on-august-11-07926bc61e969f5fPharma Surgeen2026-07-28T13:00:00.000ZCodexis to Report Second Quarter 2026 Financial Results on August 11https://www.pharmaradar360.com/article/drug-alerts-and-statements-65b7066201a76f64Pharma Surgeen2026-07-28T12:53:50.000ZDrug Alerts and Statementshttps://www.pharmaradar360.com/article/boston-scientific-unveils-major-restructuring-plots-job-cuts-amid-savings-drive-1f6af1a4b38dcf44Pharma Surgeen2026-07-28T12:45:47.000ZBoston Scientific unveils major restructuring, plots job cuts amid savings drivehttps://www.pharmaradar360.com/article/botulism-clinical-and-public-health-management-3a0db3039f9af2daPharma Surgeen2026-07-28T12:44:39.000ZBotulism: clinical and public health managementhttps://www.pharmaradar360.com/article/vanguard-health-care-etf-outperforms-vaneck-biotech-on-returns-yield-and-fees-8c45baa13ad21d52Pharma Surgeen2026-07-28T12:44:28.000ZVanguard Health Care ETF Outperforms VanEck Biotech on Returns, Yield, and Feeshttps://www.pharmaradar360.com/article/withdrawn-and-expired-guidances-drugs-1057bbfe24e27904Pharma Surgeen2026-07-28T12:38:01.000ZWithdrawn and Expired Guidances | Drugshttps://www.pharmaradar360.com/article/bioscience-and-health-technology-sector-statistics-2024-to-2025-ef58022ce55fc0a8Pharma Surgeen2026-07-28T12:35:20.000ZBioscience and health technology sector statistics 2024 to 2025https://www.pharmaradar360.com/article/eu-governments-set-to-address-biotech-and-economic-security-d2cf7d28cc2f6acePharma Surgeen2026-07-28T12:33:10.000ZEU governments set to address biotech and economic securityhttps://www.pharmaradar360.com/article/relmada-therapeutics-appoints-uro-oncology-leader-bipin-dalmia-as-chief-business-460f4d6b7e93e3caPharma Surgeen2026-07-28T12:30:00.000ZRelmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officerhttps://www.pharmaradar360.com/article/dasher-neuroscience-completes-patient-enrollment-in-phase-2-global-clinical-tria-72e0a88c845436f0Pharma Surgeen2026-07-28T12:12:00.000ZDasher Neuroscience Completes Patient Enrollment in Phase 2 Global Clinical Trial of Lead AI Drug Candidate YA-101 for Multiple System Atrophy (MSA)https://www.pharmaradar360.com/article/chip-parkinson-on-direct-to-patient-s-big-year-8b84c93737b2160dPharma Surgeen2026-07-28T12:10:59.000ZChip Parkinson on Direct-to-Patient's Big Yearhttps://www.pharmaradar360.com/article/gsk-to-establish-new-flagship-r-d-centre-on-cambridge-biomedical-campus-uk-d462784826bc48acPharma Surgeen2026-07-28T12:05:00.000ZGSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UKhttps://www.pharmaradar360.com/article/five-gate-framework-proposed-for-india-uk-pharmaceutical-trade-agreement-impleme-01d17c36777b8700Pharma Surgeen2026-07-28T12:00:43.000ZFive-Gate Framework Proposed for India-UK Pharmaceutical Trade Agreement Implementationhttps://www.pharmaradar360.com/article/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum-plans-ann-ae63a73c0ac613eaPharma Surgeen2026-07-28T12:00:00.000ZGSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026https://www.pharmaradar360.com/article/oxygen-100-gas-cylinders-containing-commercial-grade-oxygen-5de27a73ae6106b6Pharma Surgeen2026-07-28T12:00:00.000ZOxygen 100%: Gas cylinders containing commercial grade oxygenhttps://www.pharmaradar360.com/article/iqecg-digital-ecg-a3d11dca5f20b962Pharma Surgeen2026-07-28T12:00:00.000ZIQecg® Digital ECGhttps://www.pharmaradar360.com/article/a-webcast-will-carry-legend-biotech-s-q2-results-review-aug-11-0b053b3999db5775Pharma Surgeen2026-07-28T12:00:00.000ZA webcast will carry Legend Biotech's Q2 results review Aug. 11https://www.pharmaradar360.com/article/legend-biotech-to-host-investor-conference-call-on-second-quarter-2026-results-59523b86696e8d4fPharma Surgeen2026-07-28T12:00:00.000ZLegend Biotech to Host Investor Conference Call on Second Quarter 2026 Resultshttps://www.pharmaradar360.com/article/oak-hill-bio-announces-dosing-of-first-participant-in-97c7460313b876a0Pharma Surgeen2026-07-28T12:00:00.000ZOak Hill Bio Announces Dosing of First Participant inhttps://www.pharmaradar360.com/article/trevi-therapeutics-to-present-at-august-biotech-conferences-on-its-chronic-cough-649d39bbab7b9e26Pharma Surgeen2026-07-28T11:56:28.000ZTrevi Therapeutics to present at August biotech conferences on its chronic cough therapy Haduvio™https://www.pharmaradar360.com/article/jordanian-pharmaceutical-manufacturing-q2-profit-1-9-million-dinars-639626e8e10451a5Pharma Surgeen2026-07-28T11:48:10.000ZJordanian Pharmaceutical Manufacturing Q2 Profit 1.9 Million Dinarshttps://www.pharmaradar360.com/article/nasus-pharma-appoints-pharmaceutical-industry-veteran-brendan-p-o-grady-as-chief-7632a8c60fc44f0dPharma Surgeen2026-07-28T11:47:14.000ZNasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O'grady As Chief Executive Officer To Lead Strategic Growthhttps://www.pharmaradar360.com/article/nasus-pharma-appoints-pharmaceutical-industry-veteran-brendan-p-o-grady-as-chief-c929fdcd94694f1aPharma Surgeen2026-07-28T11:36:40.000ZNasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O'Grady as Chief Executive Officer to Lead Strategic Growthhttps://www.pharmaradar360.com/article/gsk-beats-consensus-forecast-in-second-quarter-a25cb9dafd3f6ce7Pharma Surgeen2026-07-28T11:33:40.000ZGSK beats consensus forecast in second quarterhttps://www.pharmaradar360.com/article/h-c-wainwright-reiterates-buy-on-legend-biotech-stock-65-target-0ecd938d13d00a9fPharma Surgeen2026-07-28T11:33:00.000ZH.C. Wainwright reiterates Buy on Legend Biotech stock, $65 targethttps://www.pharmaradar360.com/article/la-aemps-valida-un-modelo-de-gobernanza-y-un-plan-de-accion-para-facilitar-la-ap-674d611b8ecc5782Pharma Surgeen2026-07-28T11:32:00.000ZLa AEMPS valida un modelo de gobernanza y un plan de acción para facilitar la aplicación del reglamento sobre evaluación de tecnologías sanitariashttps://www.pharmaradar360.com/article/nasus-pharma-appoints-pharmaceutical-industry-veteran-brendan-p-o-grady-as-chief-98bf54978b0d70d5Pharma Surgeen2026-07-28T11:31:42.000ZNasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O'Grady as Chief Executive Officer to Lead Strategic Growthhttps://www.pharmaradar360.com/article/teva-pharmaceutical-industries-ltd-teva-is-rubric-capital-management-lp-s-4th-la-e9fd041a03e5bedePharma Surgeen2026-07-28T11:31:19.000ZTeva Pharmaceutical Industries Ltd. $TEVA is Rubric Capital Management LP's 4th Largest Positionhttps://www.pharmaradar360.com/article/grace-therapeutics-says-fda-minutes-confirm-no-clinical-safety-or-efficacy-defic-785915d37d6da7e0Pharma Surgeen2026-07-28T11:13:00.000ZGrace Therapeutics Says FDA Minutes Confirm No Clinical Safety or Efficacy Deficiencies in GTx-104 Review, Advances Dual-Source Manufacturing Plan Toward NDA Resubmissionhttps://www.pharmaradar360.com/article/atea-pharmaceuticals-reports-positive-phase-3-c-beyond-results-for-bemnifosbuvir-b672798e164a69aaPharma Surgeen2026-07-28T11:13:00.000ZAtea Pharmaceuticals Reports Positive Phase 3 C-BEYOND Results for Bemnifosbuvir/Ruzasvir in Hepatitis C, Achieving Non-Inferiority to Epclusahttps://www.pharmaradar360.com/article/gsk-s-licensor-hansoh-pharma-announces-positive-results-from-a-second-phase-iii-c71f835e3515377bPharma Surgeen2026-07-28T11:00:41.000ZGSK’s licensor Hansoh Pharma announces positive results from a second phase III trial for Ris-Rez in Chinahttps://www.pharmaradar360.com/article/field-safety-notices-20-to-24-july-2026-69b19fa2554c8c6aPharma Surgeen2026-07-28T10:57:23.000ZField Safety Notices: 20 to 24 July 2026https://www.pharmaradar360.com/article/keeping-technology-focused-on-what-matters-most-people-and-purpose-b68c638a5224e8ccPharma Surgeen2026-07-28T10:54:57.000ZKeeping technology focused on what matters most – People and purposehttps://www.pharmaradar360.com/article/insiders-in-kane-biotech-still-down-40-on-ca-1-70m-investment-0a561a9fc280cbf5Pharma Surgeen2026-07-28T10:41:41.000ZInsiders In Kane Biotech Still Down 40% On CA$1.70m Investmenthttps://www.pharmaradar360.com/article/fda-approves-first-over-the-counter-tylenol-naproxen-tab-for-12-hour-pain-relief-3d919f1f5dd371bdPharma Surgeen2026-07-28T10:37:01.000ZFDA approves first over-the-counter Tylenol & Naproxen tab for 12-hour pain reliefhttps://www.pharmaradar360.com/article/sihuan-pharmaceutical-holdings-group-sehk-460-looks-pricey-on-2026-earnings-guid-45923f119668783aPharma Surgeen2026-07-28T10:29:36.000ZSihuan Pharmaceutical Holdings Group (SEHK:460) Looks Pricey On 2026 Earnings Guidancehttps://www.pharmaradar360.com/article/2-2026-3d4545abaa6970e3Pharma Surgeen2026-07-28T10:23:46.000ZΝέα ΣΥΦΑ 2ου Τριμήνου 2026 _ Τιμολόγηση Φαρμακευτικών Προϊόντωνhttps://www.pharmaradar360.com/article/china-s-biotech-rise-to-face-challenges-from-us-policy-responses-e2d1068d210304aePharma Surgeen2026-07-28T10:18:45.000ZChina's biotech rise to face challenges from US policy responseshttps://www.pharmaradar360.com/article/singapore-hst-medical-acquired-by-kowa-pharmaceutical-asia-to-scale-health-brand-4d940b621e14414cPharma Surgeen2026-07-28T10:15:09.000ZSingapore: HST Medical acquired by Kowa Pharmaceutical Asia to scale health brands globallyhttps://www.pharmaradar360.com/article/preliminary-trial-results-suggest-a-path-to-a-safer-alzheimer-s-treatment-a7ed38bb8868b3c4Pharma Surgeen2026-07-28T10:03:32.000ZPreliminary trial results suggest a path to a safer Alzheimer’s treatmenthttps://www.pharmaradar360.com/article/integrated-care-pathway-in-individuals-with-long-covid-stimulate-icp-a-cluster-r-0337d2c2ee35d421Pharma Surgeen2026-07-28T09:50:54.000ZIntegrated care pathway in individuals with Long COVID: STIMULATE-ICP, a cluster-randomized, phase 3 trialhttps://www.pharmaradar360.com/article/eaa57ee999d15ac1Pharma Surgeen2026-07-28T09:38:36.000ZΤιμολόγηση Νέων _ Τελικά Προϊόντα Φαρμακευτικής Κάνναβης _ Προτεινόμενες Τιμές προς Διαβούλευσηhttps://www.pharmaradar360.com/article/sbi-securities-starts-takeda-pharmaceutical-at-neutral-with-5-400-yen-price-targ-5c3b127791d9ac69Pharma Surgeen2026-07-28T09:17:50.000ZSBI Securities Starts Takeda Pharmaceutical at Neutral with 5,400 Yen Price Targethttps://www.pharmaradar360.com/article/parkinson-s-disease-drug-trial-extended-following-early-findings-78961416ed0f1884Pharma Surgeen2026-07-28T09:16:55.000ZParkinson’s Disease Drug Trial Extended Following Early Findingshttps://www.pharmaradar360.com/article/hlb-pep-registers-antidiuretic-hormone-treatment-vasopressin-api-with-u-s-fda-d3f4855c011385eePharma Surgeen2026-07-28T09:08:39.000ZHLB PEP registers antidiuretic hormone treatment ‘Vasopressin’ API with U.S. FDAhttps://www.pharmaradar360.com/article/jyong-biotech-highlights-multi-billion-dollar-global-bph-market-opportunity-and-c88d4ea5fc9f7c7fPharma Surgeen2026-07-28T08:49:42.000ZJyong Biotech Highlights Multi-Billion Dollar Global BPH Market Opportunity and Reaffirms Strategic Focus on Global Licensing Partnershipshttps://www.pharmaradar360.com/article/biotech-growth-makes-14-times-return-on-forte-biosciences-accepting-2-2bn-bid-fr-3355ce7fd1f4f0c7Pharma Surgeen2026-07-28T08:48:48.000ZBiotech Growth makes 14-times return on Forte Biosciences accepting $2.2bn bid from Argenx SEhttps://www.pharmaradar360.com/article/from-lost-cause-to-gold-rush-biotechs-swarm-to-cure-aatd-435d38579c315829Pharma Surgeen2026-07-28T08:33:21.000ZFrom ‘lost cause’ to gold rush: Biotechs swarm to cure AATDhttps://www.pharmaradar360.com/article/communicable-disease-outbreak-management-guidance-01d44b0203a04ae5Pharma Surgeen2026-07-28T08:30:01.000ZCommunicable disease outbreak management guidancehttps://www.pharmaradar360.com/article/kelun-biotech-receives-trial-notice-for-dual-payload-adc-b23bf542edf83d10Pharma Surgeen2026-07-28T08:16:21.000ZKelun-Biotech receives trial notice for dual-payload ADChttps://www.pharmaradar360.com/article/apnimed-prepares-ipo-as-mass-biotechs-near-record-year-9da8da9f335fabbbPharma Surgeen2026-07-28T08:14:00.000ZApnimed prepares IPO as Mass. biotechs near record yearhttps://www.pharmaradar360.com/article/hanmi-pharmaceutical-posts-q2-profit-surge-on-lilly-deal-and-strong-korea-sales-d02e49346854eb57Pharma Surgeen2026-07-28T07:53:00.000ZHanmi Pharmaceutical posts Q2 profit surge on Lilly deal and strong Korea sales - CHOSUNBIZhttps://www.pharmaradar360.com/article/hanmi-pharmaceutical-q2-operating-profit-surges-116-9-7053244ddcdc9ecdPharma Surgeen2026-07-28T07:48:43.000ZHanmi Pharmaceutical Q2 Operating Profit Surges 116.9%https://www.pharmaradar360.com/article/poornima-restaurant-iconic-fort-udupi-eatery-loses-food-licence-after-maharashtr-c210150f095fd02ePharma Surgeen2026-07-28T07:38:54.000ZPoornima Restaurant, Iconic Fort Udupi Eatery, Loses Food Licence After Maharashtra FDA Finds Serioushttps://www.pharmaradar360.com/article/gerresheimer-doubles-china-injectable-packaging-capacity-with-new-plant-f0d749a3fef7aa91Pharma Surgeen2026-07-28T07:38:09.000ZGerresheimer doubles China injectable packaging capacity with new planthttps://www.pharmaradar360.com/article/natural-beauty-ingredients-get-biotech-rebuild-as-crop-scarcity-rises-e7304177d81aaae4Pharma Surgeen2026-07-28T07:24:04.000ZNatural beauty ingredients get biotech rebuild as crop scarcity riseshttps://www.pharmaradar360.com/article/el-consumo-de-antibioticos-en-espana-retoma-la-senda-de-descenso-y-cae-cerca-del-961beec465b4ddcbPharma Surgeen2026-07-28T07:16:15.000ZEl consumo de antibióticos en España retoma la senda de descenso y cae cerca del 19% desde 2015https://www.pharmaradar360.com/article/us-pharma-giant-to-pay-out-7-9-billion-over-baby-powder-lawsuits-d462815da2f95ee7Pharma Surgeen2026-07-28T06:58:37.000ZUS pharma giant to pay out $7.9 billion over baby powder lawsuitshttps://www.pharmaradar360.com/article/pacira-completes-manufacturing-transition-in-pcrx-201-phase-2-trial-546fea5f19ca1b80Pharma Surgeen2026-07-28T06:56:04.000ZPacira Completes Manufacturing Transition in PCRX-201 Phase 2 Trialhttps://www.pharmaradar360.com/article/biotech-growth-trust-notes-2-2-billion-acquisition-of-forte-biosciences-b818f353a6dd8671Pharma Surgeen2026-07-28T06:44:23.000ZBiotech Growth Trust Notes $2.2 Billion Acquisition Of Forte Bioscienceshttps://www.pharmaradar360.com/article/egsedi-c2efccec61d6d7d8Pharma Surgeen2026-07-28T06:21:07.000ZΕΠΙΚΟΙΝΩΝΙΑ ΓΙΑ ΕΛΛΕΙΨΗ ΦΑΡΜΑΚΕΥΤΙΚΟΥ ΠΡΟΪΟΝΤΟΣ ΤEGSEDIhttps://www.pharmaradar360.com/article/west-pharmaceutical-services-wst-is-down-6-0-after-raising-2026-outlook-and-expa-19a614f4e1e534a1Pharma Surgeen2026-07-28T06:01:19.000ZWest Pharmaceutical Services (WST) Is Down 6.0% After Raising 2026 Outlook and Expanding Daikyo Dealhttps://www.pharmaradar360.com/article/haisco-pharmaceutical-group-co-ltd-class-a-revenue-breakdown-szse-002653-93c4279019a6939cPharma Surgeen2026-07-28T05:10:18.000ZHaisco Pharmaceutical Group Co. Ltd. Class A Revenue Breakdown – SZSE:002653https://www.pharmaradar360.com/article/sls-stock-hits-1-month-low-on-china-arbitration-blow-retail-bulls-call-it-a-noth-a0f22d1815ba124fPharma Surgeen2026-07-28T05:06:00.000ZSLS Stock Hits 1-Month Low On China Arbitration Blow — Retail Bulls Call It A ‘Nothingburger’ Ahead Of AML Readouthttps://www.pharmaradar360.com/article/fda-expert-panel-backs-compounding-of-six-peptides-3ceac973b972eb63Pharma Surgeen2026-07-28T05:01:42.000ZFDA Expert Panel Backs Compounding of Six Peptideshttps://www.pharmaradar360.com/article/fda-suspends-license-of-mumbai-s-six-decade-old-udupi-eatery-poornima-restaurant-0105269ecf4c7dffPharma Surgeen2026-07-28T04:51:11.000ZFDA suspends license of Mumbai’s six-decade-old Udupi eatery Poornima Restauranthttps://www.pharmaradar360.com/article/sihuan-pharmaceutical-updates-bermuda-registered-office-address-89e6475c9152ddf6Pharma Surgeen2026-07-28T04:50:52.000ZSihuan Pharmaceutical Updates Bermuda Registered Office Addresshttps://www.pharmaradar360.com/article/aekyung-industrial-and-dong-sung-pharmaceutical-collaborate-with-fudan-universit-53bb7c7f8b5fb40cPharma Surgeen2026-07-28T04:40:00.000ZAekyung Industrial and Dong Sung Pharmaceutical Collaborate with Fudan University on Dermatology and Beauty Researchhttps://www.pharmaradar360.com/article/viral-acne-removal-cream-brand-set-to-launch-ipo-a-breakthrough-moment-for-the-i-23690aab71ba4507Pharma Surgeen2026-07-28T04:32:28.000ZViral Acne Removal Cream Brand Set to Launch IPO: A Breakthrough Moment for the Internet-Famous Skincare Labelhttps://www.pharmaradar360.com/article/global-pharmaceutical-surfactants-market-size-share-worth-usd-6-93-billion-by-20-4f4ee897724ba944Pharma Surgeen2026-07-28T04:30:00.000ZGlobal Pharmaceutical Surfactants Market Size/Share Worth USD 6.93 Billion by 2035 at a 4.42% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)https://www.pharmaradar360.com/article/sihuan-pharmaceutical-flags-217-profit-surge-on-medical-aesthetics-and-portfolio-a14d079bd78c542cPharma Surgeen2026-07-28T04:18:16.000ZSihuan Pharmaceutical Flags 217% Profit Surge on Medical Aesthetics and Portfolio Gainshttps://www.pharmaradar360.com/article/interview-how-tragedy-changed-the-fda-bcce3fbc45661da6Pharma Surgeen2026-07-28T04:01:29.000ZInterview: How Tragedy Changed the FDAhttps://www.pharmaradar360.com/article/fda-advisers-dismiss-safety-warnings-back-4-peptide-treatments-4f55b7d9383d5007Pharma Surgeen2026-07-28T04:00:00.000ZFDA Advisers Dismiss Safety Warnings, Back 4 Peptide Treatmentshttps://www.pharmaradar360.com/article/arrowhead-pharmaceuticals-completes-enrollment-in-global-phase-3-yosemite-study-04b9ba00c1862d2ePharma Surgeen2026-07-28T03:34:04.000ZArrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemiahttps://www.pharmaradar360.com/article/using-compounded-glp-1-drugs-here-s-what-doctors-want-you-to-know-b4914d175b8aa4f0Pharma Surgeen2026-07-28T03:30:00.000ZUsing Compounded GLP-1 Drugs? Here's What Doctors Want You to Knowhttps://www.pharmaradar360.com/article/should-teva-s-branded-drug-pivot-and-duvakitug-bet-reshape-how-teva-investors-vi-eb53333f9af164cfPharma Surgeen2026-07-28T03:11:15.000ZShould Teva’s Branded-Drug Pivot and Duvakitug Bet Reshape How TEVA Investors View Earnings Power?https://www.pharmaradar360.com/article/ibento-ibento-asean-japan-medical-devices-regulatory-symposium-2026-report-75a24348222fa8f5Pharma Surgeen2026-07-28T03:00:00.000Z[IBENTO][IBENTO]ASEAN-Japan Medical Devices Regulatory Symposium 2026 Reporthttps://www.pharmaradar360.com/article/argent-biopharma-finalizes-us-5-5-million-cannepil-licensing-deal-with-splash-be-54cf2b0f1a21e5c3Pharma Surgeen2026-07-28T02:45:00.000ZArgent BioPharma Finalizes US$5.5 Million CannEpil® Licensing Deal with Splash Beverage Group, Eliminates Major Debthttps://www.pharmaradar360.com/article/otsuka-to-present-pivotal-two-year-egfr-results-from-the-phase-3-visionary-trial-45d4faa6860e29f7Pharma Surgeen2026-07-28T02:21:37.000ZOtsuka to Present Pivotal Two-Year eGFR Results from the Phase 3 VISIONARY Trial of VOYXACT® (sibeprenlimab-szsi) in IgA Nephropathy (IgAN) at GlomCon Hawaii 2026https://www.pharmaradar360.com/article/selling-us-5-8m-of-stock-was-lucrative-decision-for-genscript-biotech-insiders-182b229f29279dfaPharma Surgeen2026-07-28T02:05:42.000ZSelling US$5.8m Of Stock Was Lucrative Decision For Genscript Biotech Insidershttps://www.pharmaradar360.com/article/study-examined-the-effectiveness-of-antibody-injection-simulations-d34133ed25660b67Pharma Surgeen2026-07-28T01:48:00.000ZStudy Examined The Effectiveness of Antibody Injection Simulationshttps://www.pharmaradar360.com/article/yubo-international-biotech-limited-revenue-breakdown-otc-ybgj-b0e56438f8fb47baPharma Surgeen2026-07-28T01:40:49.000ZYubo International Biotech Limited Revenue Breakdown – OTC:YBGJhttps://www.pharmaradar360.com/article/restricting-illicit-synthetic-drugs-a-complicated-challenge-590a0af845fe4228Pharma Surgeen2026-07-28T01:35:31.000ZRestricting illicit synthetic drugs a complicated challengehttps://www.pharmaradar360.com/article/bayer-opens-global-innovation-network-to-korean-biotech-startups-6a04ee79e66da6a2Pharma Surgeen2026-07-28T01:31:14.000ZBayer opens global innovation network to Korean biotech startupshttps://www.pharmaradar360.com/article/hansoh-pharmaceutical-group-units-thailand-depositery-receipts-repr-0-01-sh-f40d0caa1fb0586aPharma Surgeen2026-07-28T01:07:14.000ZHansoh Pharmaceutical Group Units Thailand Depositery Receipts Repr 0.01 Shhttps://www.pharmaradar360.com/article/aribio-wraps-up-global-phase-3-trial-of-ar1001-sets-stage-for-topline-results-5df0fecae9209a84Pharma Surgeen2026-07-28T01:01:35.000ZAriBio wraps up global phase 3 trial of AR1001, sets stage for topline resultshttps://www.pharmaradar360.com/article/south-korea-transfers-liver-organoid-tech-to-daewoong-accelerates-animal-test-sh-9de94ecf022485e1Pharma Surgeen2026-07-28T00:38:00.000ZSouth Korea transfers liver organoid tech to Daewoong, accelerates animal-test shift - CHOSUNBIZhttps://www.pharmaradar360.com/article/aribio-completes-global-phase-3-alzheimer-trial-readies-topline-results-chosunbi-8071d7c86349f79fPharma Surgeen2026-07-28T00:07:00.000ZAribio completes global phase 3 Alzheimer trial, readies topline results - CHOSUNBIZhttps://www.pharmaradar360.com/article/johnson-johnson-filed-form-8-k-32182fad9363497dPharma Surgeen2026-07-28T00:00:00.000ZJohnson & Johnson filed Form 8-Khttps://www.pharmaradar360.com/article/new-lung-preservation-machine-could-make-hundreds-of-unused-donor-lungs-availabl-e6869085d976c07dPharma Surgeen2026-07-28T00:00:00.000ZNew lung preservation machine could make hundreds of unused donor lungs available for transplanthttps://www.pharmaradar360.com/article/view-all-news-articles-c59e11b18e2ad94dPharma Surgeen2026-07-28T00:00:00.000ZView all news articleshttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-dda4283a15b84391Pharma Surgeen2026-07-28T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-e0c2cb2a24fc77a6Pharma Surgeen2026-07-28T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-olaparib-tablets-from-the-united-states-fo-267f638a261099a2Pharma Surgeen2026-07-28T00:00:00.000Znatco receives tentative approval for olaparib tablets from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-c109ecdb2edb95c1Pharma Surgeen2026-07-28T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-57ba9a964d9e29c3Pharma Surgeen2026-07-28T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-f229319aaa236589Pharma Surgeen2026-07-28T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-d4f6ff1935a647cdPharma Surgeen2026-07-28T00:00:00.000Znatco pharma limited completes acquisition of additional 13 25 stake in adcock ingram holdings proprietary limitedhttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-e78b8c13fcc016b9Pharma Surgeen2026-07-28T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-a55b82ff17cdbc4ePharma Surgeen2026-07-28T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-f609383198ebc5a7Pharma Surgeen2026-07-28T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-fc89936880385a33Pharma Surgeen2026-07-28T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-8fc658fe16033c3aPharma Surgeen2026-07-28T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-fa5e88723013dce3Pharma Surgeen2026-07-28T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/home-page-512e2b5d8beece4bPharma Surgeen2026-07-28T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/national-institute-of-environmental-health-sciences-amended-notice-of-meeting-d31e3b9c7c22e618Pharma Surgeen2026-07-28T00:00:00.000ZNational Institute of Environmental Health Sciences; Amended Notice of Meetinghttps://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-public-comment-requ-1f729a14a31cb5c4Pharma Surgeen2026-07-28T00:00:00.000ZAgency Information Collection Activities: Proposed Collection: Public Comment Request; Information Collection Request Title: Applicant Organizational National Provider Identifiers and Centers for Medicare & Medicaid Services Certification Numbers Formhttps://www.pharmaradar360.com/article/gene-m-koop-d-d-s-decision-and-order-b2e731fbf3f3038dPharma Surgeen2026-07-28T00:00:00.000ZGene M. Koop, D.D.S.; Decision and Orderhttps://www.pharmaradar360.com/article/kerri-zavota-dvm-decision-and-order-7dbd7256b445413dPharma Surgeen2026-07-28T00:00:00.000ZKerri Zavota, DVM; Decision and Orderhttps://www.pharmaradar360.com/article/cancer-clinical-trial-eligibility-criteria-laboratory-values-guidance-for-indust-3f23934bf9126791Pharma Surgeen2026-07-28T00:00:00.000ZCancer Clinical Trial Eligibility Criteria: Laboratory Values; Guidance for Industry, Institutional Review Boards, and Clinical Investigators; Availabilityhttps://www.pharmaradar360.com/article/cancer-clinical-trial-eligibility-criteria-washout-periods-and-concomitant-medic-5114e789b7635dbdPharma Surgeen2026-07-28T00:00:00.000ZCancer Clinical Trial Eligibility Criteria: Washout Periods and Concomitant Medications; Guidance for Industry, Institutional Review Boards, and Clinical Investigators; Availabilityhttps://www.pharmaradar360.com/article/cancer-clinical-trial-eligibility-criteria-performance-status-guidance-for-indus-fcb58342ba8d5f8bPharma Surgeen2026-07-28T00:00:00.000ZCancer Clinical Trial Eligibility Criteria: Performance Status; Guidance for Industry, Institutional Review Boards, and Clinical Investigators; Availabilityhttps://www.pharmaradar360.com/article/center-for-scientific-review-notice-of-closed-meeting-be62115024dfaea1Pharma Surgeen2026-07-28T00:00:00.000ZCenter for Scientific Review; Notice of Closed Meetinghttps://www.pharmaradar360.com/article/designation-of-a-class-of-employees-for-addition-to-the-special-exposure-cohort-565ee7115d765126Pharma Surgeen2026-07-28T00:00:00.000ZDesignation of a Class of Employees for Addition to the Special Exposure Cohorthttps://www.pharmaradar360.com/article/notice-of-final-issuance-on-the-adoption-of-administration-for-native-americans-34484207ae4e98b4Pharma Surgeen2026-07-28T00:00:00.000ZNotice of Final Issuance on the Adoption of Administration for Native Americans Program Policies and Procedureshttps://www.pharmaradar360.com/article/pediatric-advisory-committee-pac-notice-of-meeting-establishment-of-a-public-doc-dcac598c7fc77646Pharma Surgeen2026-07-28T00:00:00.000ZPediatric Advisory Committee (PAC); Notice of Meeting; Establishment of a Public Docket; Request for Commentshttps://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-comment-request-exp-062469215e960327Pharma Surgeen2026-07-28T00:00:00.000ZAgency Information Collection Activities; Proposed Collection; Comment Request; Expanded Access to Investigational Drugs for Treatment Usehttps://www.pharmaradar360.com/article/fee-rate-for-using-a-priority-review-voucher-in-fiscal-year-2026-correction-9ed8fad50ac365b2Pharma Surgeen2026-07-28T00:00:00.000ZFee Rate for Using a Priority Review Voucher in Fiscal Year 2026; Correctionhttps://www.pharmaradar360.com/article/pr-elidel-pimecrolimus-cream-now-reimbursed-under-alberta-s-public-drug-plan-for-5890af3cb2b97c0dPharma Surgeen2026-07-28T00:00:00.000ZPr ELIDEL ® (pimecrolimus) cream Now Reimbursed Under Alberta’s Public Drug Plan for Eligible Patients with Mild to Moderate Atopic Dermatitishttps://www.pharmaradar360.com/article/recent-developments-in-resilience-theory-and-research-a-review-across-clinical-p-347cb7d0721be88aPharma Surgeen2026-07-28T00:00:00.000ZRecent Developments in Resilience Theory and Research: A Review Across Clinical, Positive, and Organizational Psychologyhttps://www.pharmaradar360.com/article/over-600-i-u-of-insulin-per-day-in-a-pregnant-woman-with-congenital-generalized-87227f4f9c25de89Pharma Surgeen2026-07-28T00:00:00.000ZOver 600 I.U. of insulin per day in a pregnant woman with congenital generalized lipodystrophy — clinical vignettehttps://www.pharmaradar360.com/article/the-mediterranean-dietary-pattern-ameliorates-nonalcoholic-fatty-liver-disease-c-d2872bea7c71e457Pharma Surgeen2026-07-28T00:00:00.000ZThe Mediterranean Dietary Pattern Ameliorates Nonalcoholic Fatty Liver Disease: Clinical Evidence, Biological Mechanisms and Practical Implicationshttps://www.pharmaradar360.com/article/advances-in-liver-transplant-oncology-biology-driven-selection-systemic-therapy-c353ecdfb9ab44e4Pharma Surgeen2026-07-28T00:00:00.000ZAdvances in liver transplant oncology: Biology-driven selection, systemic therapy integration, and future trial frameworkshttps://www.pharmaradar360.com/article/uso-do-retalho-toracodorsal-lateral-na-reconstrucao-apos-mastectomia-cf92d81cf015d02dPharma Surgeen2026-07-28T00:00:00.000ZUso do Retalho Toracodorsal Lateral na Reconstrução Após Mastectomiahttps://www.pharmaradar360.com/article/gratification-disorder-infantile-masturbation-from-6-months-to-2-years-amp-8-mon-fd00fa71f641d46bPharma Surgeen2026-07-28T00:00:00.000ZGratification Disorder (Infantile masturbation) from 6 Months to 2 Years &amp; 8 months: A Case Analysis of Clinical Progression, Diagnostic Differentiation, and Behavioral Managementhttps://www.pharmaradar360.com/article/equine-locoregional-anaesthesia-and-analgesia-pharmacology-techniques-clinical-a-73fc1f6d449cb053Pharma Surgeen2026-07-28T00:00:00.000ZEquine Locoregional Anaesthesia and Analgesia: Pharmacology, Techniques, Clinical Applications, and Emerging Evidence in Thoracoabdominal Wall and Reproductive Tract Procedureshttps://www.pharmaradar360.com/article/clinical-outcomes-after-same-agent-double-dose-anti-vegf-escalation-in-eyes-with-212e50645008ffa1Pharma Surgeen2026-07-28T00:00:00.000ZClinical Outcomes After Same-Agent Double-Dose Anti-VEGF Escalation in Eyes with a Suboptimal Response to Standard-Dose Treatment for Exudative Macular Diseases: A Real-World Pre–Post Studyhttps://www.pharmaradar360.com/article/correction-guadalajara-et-al-impact-on-clinical-and-patient-reported-outcomes-me-2bc7ee8776dc9c7cPharma Surgeen2026-07-28T00:00:00.000ZCorrection: Guadalajara et al. Impact on Clinical- and Patient-Reported Outcomes Measures of an Organ Preservation-Based Therapeutic Strategy in Locally Advanced Rectal Cancer: The FOREST Project. J. Clin. Med. 2026, 15, 844https://www.pharmaradar360.com/article/lithium-in-bipolar-disorder-renal-mechanisms-nephrotoxicity-phenotypes-and-a-sha-33c4ec53cefb2633Pharma Surgeen2026-07-28T00:00:00.000ZLithium in Bipolar Disorder: Renal Mechanisms, Nephrotoxicity Phenotypes, and a Shared-Care Pathway for Clinical Practicehttps://www.pharmaradar360.com/article/predictrx-ai-based-decision-support-tool-for-molecular-screening-for-breast-canc-97bcf50fcd317037Pharma Surgeen2026-07-28T00:00:00.000ZPredictRx: AI based decision support tool for molecular screening for breast cancer drug recommendationhttps://www.pharmaradar360.com/article/coproporphyrin-i-pbpk-model-in-the-open-systems-pharmacology-suite-enables-preci-6a0383ad0fd1cbf2Pharma Surgeen2026-07-28T00:00:00.000ZCoproporphyrin I PBPK model in the open systems pharmacology suite enables precise prediction of OATP 1B- mediated drug interactions through calibrated In vivo inhibition constantshttps://www.pharmaradar360.com/article/clinical-utility-of-urine-drug-screening-in-children-younger-than-7-years-in-the-0f3d9b4225061b4bPharma Surgeen2026-07-28T00:00:00.000ZClinical utility of urine drug screening in children younger than 7 years in the pediatric emergency department: a multicenter retrospective studyhttps://www.pharmaradar360.com/article/a-combined-model-based-on-clinical-radiomics-and-deep-transfer-learning-features-d52bdbc920397d1fPharma Surgeen2026-07-28T00:00:00.000ZA combined model based on clinical, radiomics, and deep transfer learning features for differentiating endometrial hyperplasia with polyps from endometrial cancerhttps://www.pharmaradar360.com/article/clinical-and-genomic-characterization-of-staphylococcus-argenteus-isolates-from-96ed44660af0acb8Pharma Surgeen2026-07-28T00:00:00.000ZClinical and genomic characterization of Staphylococcus argenteus isolates from a tertiary hospital in Beijinghttps://www.pharmaradar360.com/article/clinical-utility-of-combined-serum-il-6-pct-and-saa-assays-for-early-diagnosis-a-e42c14986f22929cPharma Surgeen2026-07-28T00:00:00.000ZClinical utility of combined serum IL-6, PCT, and SAA assays for early diagnosis and severity stratification of neonatal sepsishttps://www.pharmaradar360.com/article/efficacy-and-safety-of-qing-zhu-granules-for-acute-gouty-arthritis-with-dampness-afaff4a1976802fePharma Surgeen2026-07-28T00:00:00.000ZEfficacy and safety of Qing Zhu Granules for acute gouty arthritis with dampness-heat obstruction syndrome: study protocol for a phase 3, multicenter, randomized, double-blind, placebo-controlled trialhttps://www.pharmaradar360.com/article/multimodal-natural-language-processing-in-ophthalmology-bridging-clinical-text-a-7cadf6008da6a7f6Pharma Surgeen2026-07-28T00:00:00.000ZMultimodal natural language processing in ophthalmology: bridging clinical text and medical imaginghttps://www.pharmaradar360.com/article/epithelial-cxcl1-tracks-clinical-remission-in-inflammatory-bowel-disease-in-a-di-43691187a5019549Pharma Surgeen2026-07-28T00:00:00.000ZEpithelial CXCL1 tracks clinical remission in inflammatory bowel disease in a disease-specific mannerhttps://www.pharmaradar360.com/article/revisiting-trem2-from-multi-omics-signaling-networks-to-clinical-translation-2347f8cee5a3119fPharma Surgeen2026-07-28T00:00:00.000ZRevisiting TREM2: from multi-omics signaling networks to clinical translationhttps://www.pharmaradar360.com/article/development-and-internal-validation-of-a-prediction-model-for-clinical-pregnancy-3dedb6430b02d578Pharma Surgeen2026-07-28T00:00:00.000ZDevelopment and internal validation of a prediction model for clinical pregnancy in GnRH antagonist cycles: a retrospective cohort studyhttps://www.pharmaradar360.com/article/thanatophoric-dysplasia-prevalence-clinical-characteristics-and-molecular-findin-74f0f42c9082561bPharma Surgeen2026-07-28T00:00:00.000ZThanatophoric dysplasia: prevalence, clinical characteristics, and molecular findings in a public hospital from Western Mexicohttps://www.pharmaradar360.com/article/clinical-and-molecular-characterization-of-six-mexican-patients-with-fgfr2-relat-8fa0c2156b950935Pharma Surgeen2026-07-28T00:00:00.000ZClinical and molecular characterization of six Mexican patients with FGFR2-related syndromic craniosynostosishttps://www.pharmaradar360.com/article/anti-inflammatory-diet-combined-with-exercise-improves-physical-function-and-inf-5953b440bbcf524dPharma Surgeen2026-07-28T00:00:00.000ZAnti-Inflammatory Diet Combined with Exercise Improves Physical Function and Inflammatory Profiles in Older Adults with Sarcopenia: A Randomized Controlled Trialhttps://www.pharmaradar360.com/article/peripherally-selective-cb1-receptor-antagonists-a-promising-therapeutic-strategy-e2f00814cdfdb887Pharma Surgeen2026-07-28T00:00:00.000ZPeripherally Selective CB1 Receptor Antagonists: A Promising Therapeutic Strategy for Metabolic Disordershttps://www.pharmaradar360.com/article/adverse-drug-reactions-of-non-steroidal-anti-inflammatory-drugs-in-a-tertiary-ca-ff6ee082c3bd18fcPharma Surgeen2026-07-28T00:00:00.000ZAdverse Drug Reactions of Non-Steroidal Anti-Inflammatory Drugs in a Tertiary Care Hospital in Keralahttps://www.pharmaradar360.com/article/anti-inflammatory-and-antioxidant-mechanisms-of-glp-1-receptor-agonists-molecula-dac43dbb7809b3abPharma Surgeen2026-07-28T00:00:00.000ZAnti-Inflammatory and Antioxidant Mechanisms of GLP-1 Receptor Agonists: Molecular Pathways and Therapeutic Implicationshttps://www.pharmaradar360.com/article/herbal-neurotherapeutics-in-alzheimer-s-disease-a-comprehensive-review-of-tradit-ce0f9691e77f3880Pharma Surgeen2026-07-28T00:00:00.000ZHerbal Neurotherapeutics in Alzheimer’s Disease: A Comprehensive Review of Traditional Cognitive-Enhancing Medicinal Plantshttps://www.pharmaradar360.com/article/analytical-validation-of-murcchana-on-the-stability-and-phytochemical-profile-of-5c117a3e00d123ecPharma Surgeen2026-07-28T00:00:00.000ZAnalytical Validation of 'Murcchana' on the Stability and Phytochemical Profile of Sunthi Ghrita: A Comparative Studyhttps://www.pharmaradar360.com/article/clinical-utility-of-routine-umbilical-cord-blood-screening-for-abo-incompatibili-32a36e78477efb64Pharma Surgeen2026-07-28T00:00:00.000ZClinical Utility of Routine Umbilical Cord Blood Screening for ABO Incompatibility: A Single-Center Observational Studyhttps://www.pharmaradar360.com/article/evaluating-cobas-sup-sup-b101-for-lipid-profile-and-score2-risk-assessment-from-d22ab6e337da4164Pharma Surgeen2026-07-28T00:00:00.000ZEvaluating Cobas ^® b101 for lipid profile and SCORE2 risk assessment from capillary blood in population screeninghttps://www.pharmaradar360.com/article/clinical-feasibility-of-low-magnification-fluorescence-imaging-for-breast-cancer-947564bca21dd660Pharma Surgeen2026-07-28T00:00:00.000ZClinical Feasibility of Low-Magnification Fluorescence Imaging for Breast Cancer Margin Detection Using Texture Analysis and Deep Learninghttps://www.pharmaradar360.com/article/modified-release-hydrocortisone-for-female-fertility-in-congenital-adrenal-hyper-857944536144ef9aPharma Surgeen2026-07-28T00:00:00.000ZModified-Release Hydrocortisone for Female Fertility in Congenital Adrenal Hyperplasiahttps://www.pharmaradar360.com/article/efficacy-of-yeast-mannan-supplementation-on-increasing-stool-frequency-in-adults-a237c97affa4592cPharma Surgeen2026-07-28T00:00:00.000ZEfficacy of yeast mannan supplementation on increasing stool frequency in adults: a randomized controlled trialhttps://www.pharmaradar360.com/article/expression-and-clinical-significance-of-mir-34a-5p-in-lumbar-disc-herniation-e279da012cda8e88Pharma Surgeen2026-07-28T00:00:00.000ZExpression and clinical significance of miR-34a-5p in lumbar disc herniationhttps://www.pharmaradar360.com/article/effectiveness-of-using-bite-turbos-on-temporary-implant-crowns-for-intrusion-in-bca5ecc2694771acPharma Surgeen2026-07-28T00:00:00.000ZEffectiveness of using bite turbos on temporary implant crowns for intrusion in clear aligner therapy: a clinical retrospective studyhttps://www.pharmaradar360.com/article/divergent-k-wires-in-the-sagittal-plane-have-minimal-impact-on-fixation-stabilit-4b477431191b832cPharma Surgeen2026-07-28T00:00:00.000ZDivergent K-wires in the sagittal plane have minimal impact on fixation stability and the resulting early clinical outcomes in patients with transverse patellar fractureshttps://www.pharmaradar360.com/article/modified-fourth-generation-minimally-invasive-technique-with-a-modified-k-wire-f-ff64cb9013123a9ePharma Surgeen2026-07-28T00:00:00.000ZModified fourth-generation minimally invasive technique with a modified K-wire fixation technique for hallux valgus: a biomechanical and clinical studyhttps://www.pharmaradar360.com/article/effects-of-health-promotion-behavior-education-in-pregnancy-on-sleep-quality-and-a6b947513f67063cPharma Surgeen2026-07-28T00:00:00.000ZEffects of health promotion behavior education in pregnancy on sleep quality and physical activity: a randomized controlled trialhttps://www.pharmaradar360.com/article/government-commissions-of-inquiry-and-moralities-in-swedish-drug-policymaking-4719a8d3e29441d3Pharma Surgeen2026-07-28T00:00:00.000ZGovernment Commissions of Inquiry and Moralities in Swedish Drug Policymakinghttps://www.pharmaradar360.com/article/heterogeneity-in-the-association-between-antihypertensive-medications-and-alzhei-6e944f7386c28934Pharma Surgeen2026-07-28T00:00:00.000ZHeterogeneity in the association between antihypertensive medications and Alzheimer's disease and related dementias risk: A multidimensional machine learning analysis to inform drug repurposinghttps://www.pharmaradar360.com/article/significant-elevation-in-transaminase-levels-following-the-use-of-paliperidone-i-a6f065d0e2d5d12ePharma Surgeen2026-07-28T00:00:00.000ZSignificant Elevation in Transaminase Levels Following the Use of Paliperidone in the Treatment of Acute Maniahttps://www.pharmaradar360.com/article/clinical-efficacy-and-brain-volumetric-changes-in-pediatric-onset-multiple-scler-54ea127c57aeb56cPharma Surgeen2026-07-28T00:00:00.000ZClinical Efficacy and Brain Volumetric Changes in Pediatric-Onset Multiple Sclerosis Under Teriflunomide Treatmenthttps://www.pharmaradar360.com/article/multiyear-recurrent-pericarditis-disease-duration-clinical-outcomes-after-cessat-8509e61159d32c42Pharma Surgeen2026-07-28T00:00:00.000ZMultiyear Recurrent Pericarditis Disease Duration: Clinical Outcomes After Cessation of Long‐Term Interleukin‐1 Pathway Inhibition Provide Insights for Chronic Managementhttps://www.pharmaradar360.com/article/opportunistic-coronary-artery-calcium-screening-time-for-clinical-implementation-2c77f15c04acd057Pharma Surgeen2026-07-28T00:00:00.000ZOpportunistic Coronary Artery Calcium Screening: Time for Clinical Implementationhttps://www.pharmaradar360.com/article/response-by-rodes-cabau-et-al-to-letter-regarding-article-short-term-anticoagula-e216b7fbab13ec22Pharma Surgeen2026-07-28T00:00:00.000ZResponse by Rodés-Cabau et al to Letter Regarding Article, “Short-Term Anticoagulation Versus Dual Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure: The ANDES Randomized Clinical Trial”https://www.pharmaradar360.com/article/letter-by-li-and-xiong-regarding-article-short-term-anticoagulation-versus-dual-435bde17c739735fPharma Surgeen2026-07-28T00:00:00.000ZLetter by Li and Xiong Regarding Article, “Short-Term Anticoagulation Versus Dual Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure: The ANDES Randomized Clinical Trial”https://www.pharmaradar360.com/article/prevalence-of-peri-implantitis-around-zirconia-implants-a-systematic-review-and-f60a5ff44a8eab35Pharma Surgeen2026-07-28T00:00:00.000ZPrevalence of Peri‐Implantitis Around Zirconia Implants: A Systematic Review and Meta‐Analysis of Current Evidencehttps://www.pharmaradar360.com/article/macular-telangiectasia-type-2-genetic-risk-variants-associated-with-clinical-cha-4bb9e74d28e1ac72Pharma Surgeen2026-07-28T00:00:00.000ZMacular telangiectasia type 2 genetic risk variants associated with clinical characteristics in the Slovenian cohorthttps://www.pharmaradar360.com/article/performance-verses-prevention-an-exploration-of-elite-coaches-attitudes-toward-h-9fcdda239afea4a1Pharma Surgeen2026-07-28T00:00:00.000ZPerformance Verses Prevention? An Exploration of Elite Coaches' Attitudes Toward Heading and the Implementation of English Heading Guidelineshttps://www.pharmaradar360.com/article/incidence-and-clinical-significance-of-retropharyngeal-edema-in-node-first-prese-fe60acc62f80bfa2Pharma Surgeen2026-07-28T00:00:00.000ZIncidence and Clinical Significance of Retropharyngeal Edema in Node-first Presentation of Kawasaki Diseasehttps://www.pharmaradar360.com/article/validated-1-year-mortality-prediction-in-patients-with-three-vessel-disease-unde-9a96bf05d435652aPharma Surgeen2026-07-28T00:00:00.000ZValidated 1-Year Mortality Prediction in Patients with Three-Vessel Disease Undergoing Contemporary PCI: Insights from the Multivessel TALENT trialhttps://www.pharmaradar360.com/article/right-antibiotic-right-discharge-ethical-tensions-between-antimicrobial-stewards-18039f747dd89e98Pharma Surgeen2026-07-28T00:00:00.000ZRight Antibiotic, Right Discharge: Ethical Tensions Between Antimicrobial Stewardship and Social Vulnerabilityhttps://www.pharmaradar360.com/article/the-burden-of-hiv-related-stigma-on-clinical-and-quality-of-life-outcomes-result-91d8e71a0076a8a3Pharma Surgeen2026-07-28T00:00:00.000ZThe burden of HIV-related stigma on clinical and quality of life outcomes: results from a systematic literature reviewhttps://www.pharmaradar360.com/article/could-glp-1ras-improve-outcomes-for-patients-with-chronic-migraine-71d70bba659631c8Pharma Surgeen2026-07-28T00:00:00.000ZCould GLP-1RAs improve outcomes for patients with chronic migraine?https://www.pharmaradar360.com/article/diagnosis-of-traumatic-diaphragmatic-injury-remains-a-clinical-challenge-brief-r-2513aadc6f7ce58bPharma Surgeen2026-07-28T00:00:00.000ZDiagnosis of traumatic diaphragmatic injury remains a clinical challenge - Brief reporthttps://www.pharmaradar360.com/article/design-and-i-in-vivo-i-pharmacokinetic-evaluation-of-a-once-daily-immediate-and-0312a88c90bc8ec6Pharma Surgeen2026-07-28T00:00:00.000ZDesign and <i>in vivo</i> pharmacokinetic evaluation of a once-daily immediate- and extended-release bilayer tablet of bepotastine salicylatehttps://www.pharmaradar360.com/article/periodontal-disease-and-cardiovascular-events-mechanisms-biomarkers-and-clinical-884e064830104fe4Pharma Surgeen2026-07-28T00:00:00.000ZPeriodontal disease and cardiovascular events: mechanisms, biomarkers, and clinical translationhttps://www.pharmaradar360.com/article/probiotic-effects-on-brain-health-are-both-transient-and-sustained-for-several-w-fda30f2583660a4ePharma Surgeen2026-07-28T00:00:00.000ZProbiotic effects on brain health are both transient and sustained for several weeks after discontinuation: a randomised controlled trialhttps://www.pharmaradar360.com/article/subsistence-input-rates-limit-farming-systems-potential-in-a-longterm-on-farm-tr-0451fd11b80f1a77Pharma Surgeen2026-07-28T00:00:00.000ZSubsistence input rates limit farming systems’ potential in a longterm on-farm trial in Central Kenyahttps://www.pharmaradar360.com/article/integration-of-a-clinical-survival-model-into-the-km-plotter-to-identify-high-ri-a493d948b503a410Pharma Surgeen2026-07-28T00:00:00.000ZIntegration of a clinical survival model into the KM-plotter to identify high-risk populations in breast cancerhttps://www.pharmaradar360.com/article/the-impacts-of-beta-globin-gene-mutations-and-xmn-ig-polymorphism-hbg2-c-211-c-g-3ac7c3995ab120ccPharma Surgeen2026-07-28T00:00:00.000ZThe impacts of beta globin gene mutations and Xmn IGγ polymorphism (HBG2 c. -211 C &gt; T) on the clinical features of Hb Eβ-thalassemia patients in Bangladeshhttps://www.pharmaradar360.com/article/maternal-6-valent-group-b-streptococcus-vaccine-in-non-pregnant-and-pregnant-fem-00e698843680f66cPharma Surgeen2026-07-28T00:00:00.000ZMaternal 6-valent group B Streptococcus vaccine in non-pregnant and pregnant females: a randomized phase 1/2 trialhttps://www.pharmaradar360.com/article/deep-learning-methods-for-detection-of-stroke-for-neuropathology-lessons-learned-a18c25b287661189Pharma Surgeen2026-07-28T00:00:00.000ZDeep Learning Methods for Detection of Stroke for Neuropathology: Lessons learned from <i>In‑Vivo</i> Imaging to Digital Pathologyhttps://www.pharmaradar360.com/article/autologous-peripheral-blood-derived-stem-cells-combined-with-platelet-rich-plasm-f432247aae708e15Pharma Surgeen2026-07-28T00:00:00.000ZAutologous Peripheral Blood-Derived Stem Cells Combined with Platelet-Rich Plasma is Associated With Clinical and Radiological Improvement in Anterior Cruciate Ligament Ruptures—Preliminary Clinical and MRI Findings in 47 Consecutive Patientshttps://www.pharmaradar360.com/article/career-paths-to-drug-development-and-regulatory-science-through-the-u-s-food-and-5daf54dd26c582d6Pharma Surgeen2026-07-28T00:00:00.000ZCareer Paths to Drug Development and Regulatory Science Through the U.S. Food and Drug Administrationhttps://www.pharmaradar360.com/article/drug-specific-differences-in-fatal-adverse-events-among-parp-inhibitors-a-faers-ec0e9bdf5a7cfaadPharma Surgeen2026-07-28T00:00:00.000ZDrug-specific differences in fatal adverse events among PARP inhibitors: a FAERS pharmacovigilance studyhttps://www.pharmaradar360.com/article/impact-of-press-needle-combining-breast-massage-on-onset-of-lactogenesis-ii-in-p-34057b1d259941a5Pharma Surgeen2026-07-28T00:00:00.000ZImpact of Press Needle Combining Breast Massage on Onset of Lactogenesis II in Post-Cesarean Mothers: A Randomized Controlled Trialhttps://www.pharmaradar360.com/article/efficacy-and-safety-of-zizhu-ointment-for-wagner-grade-2-diabetic-foot-ulcers-a-06d72eb24d482c2bPharma Surgeen2026-07-28T00:00:00.000ZEfficacy and Safety of Zizhu Ointment for Wagner Grade 2 Diabetic Foot Ulcers: A Single-Center, Randomized, Double-Blind, Placebo-Controlled Trialhttps://www.pharmaradar360.com/article/molecular-characterization-of-lactamase-genes-and-porin-alterations-in-multidrug-d0e0ae1a0c704e65Pharma Surgeen2026-07-28T00:00:00.000ZMolecular characterization of β-lactamase genes and porin alterations in multidrug-resistant Gram-negative clinical isolates from Calabria, Southern Italyhttps://www.pharmaradar360.com/article/advancing-in-personalization-of-psychological-indicated-preventive-interventions-f99c921efce6337dPharma Surgeen2026-07-28T00:00:00.000ZAdvancing in Personalization of Psychological, Indicated Preventive Interventions: A Randomized Controlled Trial in Adolescents at High-Risk of Developing Emotional Disordershttps://www.pharmaradar360.com/article/genomic-analysis-of-streptococcus-pyogenes-emm1-type-isolates-reveals-m1uk-circu-5126d51000e8404dPharma Surgeen2026-07-28T00:00:00.000ZGenomic analysis of Streptococcus pyogenes emm1-type isolates reveals M1UK circulation and a genetically distinct Brazilian sublineagehttps://www.pharmaradar360.com/article/ivarmacitinib-in-patients-with-active-ankylosing-spondylitis-subgroup-analysis-b-2a401b441e0c5d75Pharma Surgeen2026-07-28T00:00:00.000ZIvarmacitinib in patients with active ankylosing spondylitis: subgroup analysis based on key baseline features from a phase II/III trialhttps://www.pharmaradar360.com/article/the-impact-of-condylar-fracture-management-on-facial-soft-tissue-changes-and-tmj-95591c5038a7a567Pharma Surgeen2026-07-28T00:00:00.000ZThe impact of condylar fracture management on facial soft tissue changes and TMJ function: a 3D CBCT evaluation of open vs. closed reductionhttps://www.pharmaradar360.com/article/clinical-and-optical-coherence-tomography-angiography-based-risk-factors-for-red-fe0c9fc46b9f8de7Pharma Surgeen2026-07-28T00:00:00.000ZClinical and optical coherence tomography angiography-based risk factors for reduced retinal sensitivity in diabetic macular edemahttps://www.pharmaradar360.com/article/the-pre-operative-physical-component-subscale-of-the-12-item-short-form-health-s-41beee38ea7b4431Pharma Surgeen2026-07-28T00:00:00.000ZThe pre-operative physical component subscale of the 12-item Short Form Health Survey was the only factor associated with 2-year clinical outcome and satisfaction after hip abductor tendon repairhttps://www.pharmaradar360.com/article/population-pharmacokinetic-modeling-of-amisulpride-drug-interactions-and-a-trans-23383e7b68613a8bPharma Surgeen2026-07-28T00:00:00.000ZPopulation pharmacokinetic modeling of amisulpride drug interactions and a transporter binding analysishttps://www.pharmaradar360.com/article/multi-omics-mendelian-randomization-identified-adaptive-immune-response-related-76cc061b5e7f9dfcPharma Surgeen2026-07-28T00:00:00.000ZMulti-omics Mendelian randomization identified adaptive immune response–related drug targets in psoriatic arthritishttps://www.pharmaradar360.com/article/clinical-resource-use-in-patients-undergoing-intradetrusor-abotulinum-toxin-a-in-19cf03e11e1d237fPharma Surgeen2026-07-28T00:00:00.000ZClinical Resource Use in Patients Undergoing Intradetrusor Abotulinum Toxin A Injections for Neurogenic Compared to Non‐Neurogenic Indications—The Potential for Compensation Inequities for Urologic and Urogynecologic Practiceshttps://www.pharmaradar360.com/article/an-engineered-multicellular-bacterial-network-for-simultaneously-answering-multi-93d4ac23af8ca69bPharma Surgeen2026-07-28T00:00:00.000ZAn Engineered Multicellular Bacterial Network for Simultaneously Answering Multiple Computational Decision Problemshttps://www.pharmaradar360.com/article/randomized-clinical-trials-using-a-hierarchical-composite-primary-end-point-d67c0b988621ef0ePharma Surgeen2026-07-28T00:00:00.000ZRandomized Clinical Trials Using a Hierarchical Composite Primary End Pointhttps://www.pharmaradar360.com/article/nct07731659-physical-activity-intervention-for-individuals-newly-diagnosed-with-606dc37ab403c995Pharma Surgeen2026-07-28T00:00:00.000ZNCT07731659: Physical Activity Intervention for Individuals Newly Diagnosed With MShttps://www.pharmaradar360.com/article/nct07730151-efficacy-and-safety-of-darolutamide-combined-with-docetaxel-and-adt-2426f1e27e4c350cPharma Surgeen2026-07-28T00:00:00.000ZNCT07730151: Efficacy and Safety of Darolutamide Combined With Docetaxel and ADT as Neoadjuvant Therapy for Locally Advanced Prostate Cancer.https://www.pharmaradar360.com/article/nct07729852-open-label-access-to-ath434-for-patients-who-completed-study-ath434-517234f3fdb04a44Pharma Surgeen2026-07-28T00:00:00.000ZNCT07729852: Open-Label Access to ATH434 for Patients Who Completed Study ATH434-201 in Francehttps://www.pharmaradar360.com/article/nct07729774-spray-and-stretch-technique-versus-strain-counter-strain-in-patients-eb224c97558ae061Pharma Surgeen2026-07-28T00:00:00.000ZNCT07729774: Spray and Stretch Technique Versus Strain Counter Strain in Patients With Non Specific Low Back Painhttps://www.pharmaradar360.com/article/nct07715903-hepatic-artery-infusion-of-carfilzomib-in-participants-with-liver-me-c34d97c9f5173517Pharma Surgeen2026-07-28T00:00:00.000ZNCT07715903: Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapyhttps://www.pharmaradar360.com/article/nct07709494-a-phase-1a-1b-study-to-investigate-the-safety-tolerability-microbiol-bb01afd0e223c7b7Pharma Surgeen2026-07-28T00:00:00.000ZNCT07709494: A Phase 1a/1b Study to Investigate the Safety, Tolerability, Microbiological Response, and Pharmacokinetics of Inhaled Rev-56 in Adult Healthy Volunteers and Adult Non-cystic Fibrosis Bronchiectasis (NCFB) Patients With Chronic P. Aeruginosahttps://www.pharmaradar360.com/article/nct07706673-a-scientific-evaluation-of-one-or-two-doses-of-a-vaccine-against-hum-07f80effb8bbc24cPharma Surgeen2026-07-28T00:00:00.000ZNCT07706673: A Scientific Evaluation of One or Two Doses of a Vaccine Against Human Papillomavirus: Long Term Follow Up of Gardasil9 Recipients in the ESCUDDO Study ("Estudio de Comparación de Una y Dos Dosis de Vacunas Contra el Virus de Papiloma Humano [VPH]")https://www.pharmaradar360.com/article/nct07701369-relevance-of-artificial-intelligence-assisted-echocardiography-for-l-3b767f1ae0f77d50Pharma Surgeen2026-07-28T00:00:00.000ZNCT07701369: Relevance of Artificial Intelligence-Assisted Echocardiography for Left Ventricular Ejection Fraction Assessment in Geriatric Patientshttps://www.pharmaradar360.com/article/nct07692685-pharmacokinetic-effect-of-y-3-for-injection-on-rosuvastatin-calcium-f8663e7cbab38ff8Pharma Surgeen2026-07-28T00:00:00.000ZNCT07692685: Pharmacokinetic Effect of Y-3 for Injection on Rosuvastatin Calcium Tablets in Healthy Participantshttps://www.pharmaradar360.com/article/nct07633288-a-clinical-trial-evaluating-the-safety-and-efficacy-of-ap1189-versus-4c26977e22d9621ePharma Surgeen2026-07-28T00:00:00.000ZNCT07633288: A Clinical Trial Evaluating the Safety and Efficacy of AP1189 Versus Placebo as an add-on to Standard of Care in Participants With Respiratory Insufficiency Expected to be Caused by Infection With Respiratory Viruseshttps://www.pharmaradar360.com/article/nct07630961-phase-i-study-of-jfi447-68ga-ga-dfc413-and-comparison-to-ffg233-68ga-6e7e6fc45fc3ece3Pharma Surgeen2026-07-28T00:00:00.000ZNCT07630961: Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumorshttps://www.pharmaradar360.com/article/nct07596173-a-study-on-the-immune-response-and-safety-of-a-combined-vaccine-agai-3b89e675839c14adPharma Surgeen2026-07-28T00:00:00.000ZNCT07596173: A Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and Acellular Pertussis (dTpa) in Healthy Japanese Adolescents Aged 11 Years to <13 Yearshttps://www.pharmaradar360.com/article/nct07507513-the-purpose-of-this-study-is-to-evaluate-the-efficacy-and-safety-of-35fc0e59527ccf9dPharma Surgeen2026-07-28T00:00:00.000ZNCT07507513: The Purpose of This Study is to Evaluate the Efficacy and Safety of 627 in the Treatment of UChttps://www.pharmaradar360.com/article/nct07492498-novel-model-of-integrated-care-of-older-patients-with-atrial-fibrill-82a18d0b7647cbcbPharma Surgeen2026-07-28T00:00:00.000ZNCT07492498: Novel Model of Integrated Care of Older Patients With Atrial Fibrillation to Prevent Heart Failure in Rural Chinahttps://www.pharmaradar360.com/article/nct07415057-simulation-on-the-enhancement-of-clinical-communication-competencies-ac11fe31fa6e94bdPharma Surgeen2026-07-28T00:00:00.000ZNCT07415057: Simulation on the Enhancement of Clinical Communication Competencies in Nursing Studentshttps://www.pharmaradar360.com/article/nct07388550-phase-i-open-label-safety-trial-of-pembrolizumab-for-neurological-po-c8883fe8549f9913Pharma Surgeen2026-07-28T00:00:00.000ZNCT07388550: Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)https://www.pharmaradar360.com/article/nct07360067-prospective-cohort-study-of-bachmann-bundle-versus-right-atrial-appe-198c4ee5185af224Pharma Surgeen2026-07-28T00:00:00.000ZNCT07360067: Prospective Cohort Study of Bachmann Bundle Versus Right Atrial Appendage Pacing: Impact on Atrial Cardiomyopathy Evaluated by Echocardiographic Parameters and Clinical Outcomehttps://www.pharmaradar360.com/article/nct07272499-orelabrutinib-plus-lisaftoclax-and-rituximab-in-untreated-mantle-cel-d09384f91a720fb9Pharma Surgeen2026-07-28T00:00:00.000ZNCT07272499: Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Diseasehttps://www.pharmaradar360.com/article/nct07270380-antibiotic-device-for-osteomyelitis-of-the-extremities-pivotal-trial-1f7445e7e7f6990aPharma Surgeen2026-07-28T00:00:00.000ZNCT07270380: Antibiotic Device for Osteomyelitis of the Extremities Pivotal Trial - Genex With Gentamicin.https://www.pharmaradar360.com/article/nct07192432-gene-therapy-for-her-positive-cancer-sentry-her2-508f49f109c4465aPharma Surgeen2026-07-28T00:00:00.000ZNCT07192432: Gene Therapy for HER-Positive Cancer (SENTRY-HER2)https://www.pharmaradar360.com/article/nct07170527-long-term-outcomes-and-post-intensive-care-syndrome-investigating-th-6ff25de69969b210Pharma Surgeen2026-07-28T00:00:00.000ZNCT07170527: Long-Term Outcomes and Post-Intensive Care Syndrome: Investigating the Associations Between Metabolic Signatures and Physical Functioning in Critically Ill Patientshttps://www.pharmaradar360.com/article/nct06948110-deciphering-the-genetic-architecture-of-autoimmune-diseases-353665cab37b522aPharma Surgeen2026-07-28T00:00:00.000ZNCT06948110: Deciphering the Genetic Architecture of Autoimmune Diseaseshttps://www.pharmaradar360.com/article/nct06937931-a-study-of-ipn10200-for-the-treatment-of-cervical-dystonia-in-adults-680fac1f31b0b327Pharma Surgeen2026-07-28T00:00:00.000ZNCT06937931: A Study of IPN10200 for the Treatment of Cervical Dystonia in Adultshttps://www.pharmaradar360.com/article/nct06876142-combination-therapy-mirdametinib-and-sirolimus-for-ras-mutated-relap-84e0260330113171Pharma Surgeen2026-07-28T00:00:00.000ZNCT06876142: Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myelomahttps://www.pharmaradar360.com/article/nct06825559-evaluate-pk-safety-of-saroglitazar-in-subjects-with-moderate-hepatic-43197a0a58652f20Pharma Surgeen2026-07-28T00:00:00.000ZNCT06825559: Evaluate PK & Safety of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to Cholestatic Liver Diseasehttps://www.pharmaradar360.com/article/nct06694454-neoadjuvant-inhaled-azacytidine-with-platinum-based-chemotherapy-and-0c2ce5ad67f1e6f8Pharma Surgeen2026-07-28T00:00:00.000ZNCT06694454: Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)https://www.pharmaradar360.com/article/nct06510166-the-effect-of-distraction-methods-used-during-inhalation-therapy-on-16ff96b9c947ca35Pharma Surgeen2026-07-28T00:00:00.000ZNCT06510166: The Effect of Distraction Methods Used During Inhalation Therapy on Children's Fear and Anxiety: : Randomize Controlled Studyhttps://www.pharmaradar360.com/article/nct06484088-study-brain-mechanisms-of-frustration-with-magnetoencephalography-in-f69a63610584bc2cPharma Surgeen2026-07-28T00:00:00.000ZNCT06484088: Study Brain Mechanisms of Frustration With Magnetoencephalography in Healthy Volunteershttps://www.pharmaradar360.com/article/nct06422338-a-rapid-triage-test-to-improve-risk-stratification-of-febrile-childr-d24efd065b1e9b0bPharma Surgeen2026-07-28T00:00:00.000ZNCT06422338: A Rapid Triage Test to Improve Risk-stratification of Febrile Children (EChiLiBRiST, Clinical Trial 1, Outpatients)https://www.pharmaradar360.com/article/nct06325696-h01-in-adults-with-interstitial-lung-disease-the-solis-study-30ab08567fcde181Pharma Surgeen2026-07-28T00:00:00.000ZNCT06325696: H01 in Adults With Interstitial Lung Disease (The SOLIS Study)https://www.pharmaradar360.com/article/nct06199232-targeted-treatment-plus-tislelizumab-and-haic-for-advanced-crclm-fai-8097a8914811c8d4Pharma Surgeen2026-07-28T00:00:00.000ZNCT06199232: Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatmenthttps://www.pharmaradar360.com/article/nct05911269-feasibility-of-virtual-tailored-music-based-relaxation-for-anxiety-i-9415f6b06c459162Pharma Surgeen2026-07-28T00:00:00.000ZNCT05911269: Feasibility of Virtual, Tailored, Music-Based Relaxation for Anxiety in Adolescent and Young Adult Cancer Survivorshttps://www.pharmaradar360.com/article/nct05764746-triple-artemisinin-based-combination-therapy-for-delaying-drug-resis-d52564035ed63dc5Pharma Surgeen2026-07-28T00:00:00.000ZNCT05764746: Triple Artemisinin-based Combination Therapy for Delaying Drug Resistance Development - a Randomized Clinical Trialhttps://www.pharmaradar360.com/article/nct05691478-a-study-to-test-the-addition-of-the-drug-cabozantinib-to-chemotherap-faed8be82b31b368Pharma Surgeen2026-07-28T00:00:00.000ZNCT05691478: A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcomahttps://www.pharmaradar360.com/article/nct05642195-evaluation-of-a-cancer-lysate-vaccine-and-montanide-registered-trade-6c3881e00781f72dPharma Surgeen2026-07-28T00:00:00.000ZNCT05642195: Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancerhttps://www.pharmaradar360.com/article/nct05282901-efficacy-and-safety-of-pembrolizumab-in-combination-with-lenvatinib-c01dd6b390e5a240Pharma Surgeen2026-07-28T00:00:00.000ZNCT05282901: Efficacy and Safety of Pembrolizumab in Combination With Lenvatinib in Metastatic Uveal MElanoma Patients (PLUME)https://www.pharmaradar360.com/article/nct05198830-testing-the-addition-of-an-anti-cancer-drug-trc102-to-the-usual-chem-2e7a02e16da5d13cPharma Surgeen2026-07-28T00:00:00.000ZNCT05198830: Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancerhttps://www.pharmaradar360.com/article/nct05141682-oral-azacitidine-for-the-treatment-of-relapsed-or-refractory-t-cell-d927bcedde197459Pharma Surgeen2026-07-28T00:00:00.000ZNCT05141682: Oral Azacitidine for the Treatment of Relapsed or Refractory T-cell Large Granular Lymphocytic Leukemiahttps://www.pharmaradar360.com/article/nct04449549-rapid-analysis-and-response-evaluation-of-combination-anti-neoplasti-ff3252eaf85eba3cPharma Surgeen2026-07-28T00:00:00.000ZNCT04449549: Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxelhttps://www.pharmaradar360.com/article/nct02877394-use-of-a-squatting-assist-device-in-patients-with-constipation-bd5a7ff549656d0bPharma Surgeen2026-07-28T00:00:00.000ZNCT02877394: Use of a Squatting Assist Device in Patients With Constipationhttps://www.pharmaradar360.com/article/nct02821780-cadasil-disease-discovery-fb8afeba7ed2b916Pharma Surgeen2026-07-28T00:00:00.000ZNCT02821780: CADASIL Disease Discoveryhttps://www.pharmaradar360.com/article/nct02772003-dna-vaccine-therapy-in-treating-patients-with-chronic-hepatitis-c-vi-505e48e04ddf9437Pharma Surgeen2026-07-28T00:00:00.000ZNCT02772003: DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infectionhttps://www.pharmaradar360.com/article/nct02506933-multi-antigen-cmv-mva-triplex-vaccine-in-reducing-cmv-complications-af6fead1b621a44bPharma Surgeen2026-07-28T00:00:00.000ZNCT02506933: Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplanthttps://www.pharmaradar360.com/article/nct02450851-clinical-and-genetic-evaluation-of-individuals-with-undiagnosed-diso-e0d88570c8b37ef4Pharma Surgeen2026-07-28T00:00:00.000ZNCT02450851: Clinical and Genetic Evaluation of Individuals With Undiagnosed Disorders Through the Undiagnosed Diseases Networkhttps://www.pharmaradar360.com/article/nct02257892-novel-genetic-disorders-of-the-immune-system-6828edd28f6cdbe7Pharma Surgeen2026-07-28T00:00:00.000ZNCT02257892: Novel Genetic Disorders of the Immune Systemhttps://www.pharmaradar360.com/article/nct02211768-transformation-of-plexiform-neurofibromas-to-malignant-peripheral-ne-798abe7fe26ea5fdPharma Surgeen2026-07-28T00:00:00.000ZNCT02211768: Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1https://www.pharmaradar360.com/article/nct02014246-genetic-characterization-of-movement-disorders-and-dementias-88611d2050374b0cPharma Surgeen2026-07-28T00:00:00.000ZNCT02014246: Genetic Characterization of Movement Disorders and Dementiashttps://www.pharmaradar360.com/article/nct01934660-links-between-inflammation-and-cardiometabolic-diseases-cbdc4127a143ca47Pharma Surgeen2026-07-28T00:00:00.000ZNCT01934660: Links Between Inflammation and Cardiometabolic Diseaseshttps://www.pharmaradar360.com/article/nct01621581-aav2-gdnf-for-advanced-parkinson-s-disease-0df7c70891e59c45Pharma Surgeen2026-07-28T00:00:00.000ZNCT01621581: AAV2-GDNF for Advanced Parkinson s Diseasehttps://www.pharmaradar360.com/article/nct01306019-lentiviral-gene-transfer-for-treatment-of-children-older-than-two-ye-5b3abea0b8bda776Pharma Surgeen2026-07-28T00:00:00.000ZNCT01306019: Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)https://www.pharmaradar360.com/article/nct01109394-comprehensive-omics-analysis-of-pediatric-and-adult-solid-tumors-and-2ba794ed1494f44ePharma Surgeen2026-07-28T00:00:00.000ZNCT01109394: Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studieshttps://www.pharmaradar360.com/article/nct00756769-systemic-lupus-erythematosus-in-gullah-health-b9a42011a06dea75Pharma Surgeen2026-07-28T00:00:00.000ZNCT00756769: Systemic Lupus Erythematosus in Gullah Healthhttps://www.pharmaradar360.com/article/nct00341679-studies-of-the-natural-history-and-pathogenesis-of-autoimmune-connec-635ce38173f5e1adPharma Surgeen2026-07-28T00:00:00.000ZNCT00341679: Studies of the Natural History and Pathogenesis of Autoimmune/Connective Tissue Diseaseshttps://www.pharmaradar360.com/article/nct00340405-development-of-a-biologic-specimen-bank-for-the-study-of-early-marke-3426c2371f25f951Pharma Surgeen2026-07-28T00:00:00.000ZNCT00340405: Development of a Biologic Specimen Bank for the Study of Early Markers of Lung Cancer Among Tin Miners in Yunnan, Chinahttps://www.pharmaradar360.com/article/nct00250159-natural-history-study-of-patients-with-excess-androgen-c4f660d085d0650cPharma Surgeen2026-07-28T00:00:00.000ZNCT00250159: Natural History Study of Patients With Excess Androgenhttps://www.pharmaradar360.com/article/nct00077909-study-of-lung-proteins-in-patients-with-pneumonia-362bc853098da05bPharma Surgeen2026-07-28T00:00:00.000ZNCT00077909: Study of Lung Proteins in Patients With Pneumoniahttps://www.pharmaradar360.com/article/nct00006150-natural-history-management-and-genetics-of-the-hyperimmunoglobulin-e-f12d0eddaf371b6cPharma Surgeen2026-07-28T00:00:00.000ZNCT00006150: Natural History, Management, and Genetics of the Hyperimmunoglobulin E Recurrent Infection Syndrome (HIES)https://www.pharmaradar360.com/article/nct00001456-clinical-and-basic-investigations-into-hermansky-pudlak-syndrome-81dae94b2c06328bPharma Surgeen2026-07-28T00:00:00.000ZNCT00001456: Clinical and Basic Investigations Into Hermansky-Pudlak Syndromehttps://www.pharmaradar360.com/article/fda-panel-recommends-compounding-unapproved-peptides-eca7b12653bcbf15Pharma Surgeen2026-07-27T23:42:16.000ZFDA Panel Recommends Compounding Unapproved Peptideshttps://www.pharmaradar360.com/article/potential-retatrutide-benefits-you-should-know-about-ac72bb2e3d85d358Pharma Surgeen2026-07-27T23:41:03.000ZPotential Retatrutide Benefits You Should Know Abouthttps://www.pharmaradar360.com/article/aribio-completes-global-phase-3-trial-of-ar1001-topline-results-to-be-announced-0c6918cd901193bdPharma Surgeen2026-07-27T23:39:43.000ZAribio Completes Global Phase 3 Trial of AR1001... Topline Results to Be Announced in Novemberhttps://www.pharmaradar360.com/article/south-korea-joins-who-s-transitional-list-of-top-medical-device-regulators-chosu-dec4af55b9a659f0Pharma Surgeen2026-07-27T23:30:00.000ZSouth Korea joins WHO’s transitional list of top medical device regulators - CHOSUNBIZhttps://www.pharmaradar360.com/article/cooley-owes-25-4m-judgment-to-nj-biotech-co-founder-ee18815a8913be98Pharma Surgeen2026-07-27T23:23:00.000ZCooley Owes $25.4M Judgment To NJ Biotech Co. Founderhttps://www.pharmaradar360.com/article/cg-oncology-announces-lancet-oncology-publication-of-phase-3-bond-003-cohort-c-r-d701f0f0929e243cPharma Surgeen2026-07-27T22:50:00.000ZCG Oncology Announces Lancet Oncology Publication of Phase 3 BOND-003 Cohort C Results for Cretostimogene in High-Risk BCG-Unresponsive Bladder Cancerhttps://www.pharmaradar360.com/article/about-81-of-bond-003-patients-maintained-their-bladders-at-24-months-c717fcb83e480347Pharma Surgeen2026-07-27T22:49:04.000ZAbout 81% of BOND-003 patients maintained their bladders at 24 monthshttps://www.pharmaradar360.com/article/argenx-enters-biotech-buyer-class-with-2-2b-forte-takeout-4ebbf4be04fa8757Pharma Surgeen2026-07-27T21:39:00.000ZArgenx enters biotech buyer class with $2.2B Forte takeout